These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35112990)

  • 1. Long-term buprenorphine treatment for kratom use disorder: A case series.
    Broyan VR; Brar JK; Allgaier Student T; Allgaier JT
    Subst Abus; 2022; 43(1):763-766. PubMed ID: 35112990
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Kratom Withdrawal and Dependence With Buprenorphine/Naloxone: A Case Series and Systematic Literature Review.
    Weiss ST; Douglas HE
    J Addict Med; 2021 Apr; 15(2):167-172. PubMed ID: 32858563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance.
    Buresh M
    J Addict Med; 2018; 12(6):481-483. PubMed ID: 29944481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Home induction and outpatient treatment of kratom use disorder with buprenorphine-naloxone: A case report in a young adult.
    Schmuhl KK; Gardner SM; Cottrill CB; Bonny AE
    Subst Abus; 2020; 41(3):311-314. PubMed ID: 31644379
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
    Khazaeli A; Jerry JM; Vazirian M
    J Addict Med; 2018; 12(6):493-495. PubMed ID: 30383616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kratom: Substance of Abuse or Therapeutic Plant?
    Gorelick DA
    Psychiatr Clin North Am; 2022 Sep; 45(3):415-430. PubMed ID: 36055730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone.
    Brogdon HD; McPhee MM; Paine MF; Cox EJ; Burns AG
    J Addict Med; 2022 Sep-Oct 01; 16(5):606-609. PubMed ID: 35165231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 15. Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine.
    Perez J
    J Opioid Manag; 2023; 19(1):91-93. PubMed ID: 36683304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of buprenorphine + naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports.
    Ulu E; Kandeğer A; Meriç R
    J Addict Dis; 2022; 40(3):432-438. PubMed ID: 34775907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.
    Vytialingam RC; Schug SA; O'Regan R
    J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.